HealthQuill Johnson & Johnson
The UK’s Medicines and Healthcare products Regulatory Agency has approved Janssen-Cilag Limited’s guselkumab (Tremfya) to treat Crohn’s disease and ulcerative colitis.
Drugs Health Pharma

UK clears Janssen-Cilag’s drug for Crohn’s disease, ulcerative colitis

HQ Team May 19, 2025: The UK’s Medicines and Healthcare products Regulatory Agency has approved Janssen-Cilag Limited’s guselkumab (Tremfya) to treat Crohn’s disease.

Read More
Johnson & Johnson’s immune disorder drug has been approved by the US Food and Drug Administration for the treatment of generalised myasthenia gravis (gMG) — a rare disease that causes muscle weakness and affects daily activities like chewing, swallowing, speaking, and breathing.
Drugs Health Pharma

US regulator approves Johnson & Johnson’s immune disorder drug

HQ Team April 30, 2025: Johnson & Johnson’s immune disorder drug has been approved by the US Food and Drug Administration for the.

Read More
Johnson & Johnson’s investigational treatment to help people with a specific type of early-stage bladder cancer has shown 80% of the patients to be free of cancer for up to nine months, and 94% were able to avoid surgical removal of the organ after a year of follow-up.
Drugs Health Pharma

J&J’s trial drug for a type of bladder cancer helps avoid organ removal 

HQ Team April 27, 2025: Johnson & Johnson’s investigational treatment to help people with a specific type of early-stage bladder cancer has shown.

Read More
Amgen Inc. will expand its Ohio biomanufacturing facility for $900 million, after a recent move to invest $1 billion to build a second manufacturing plant in Holly Springs, North Carolina, US.
Drugs Medical Pharma

Amgen to invest $900 million in Ohio biomanufacturing facility

HQ Team April 26, 2025: Amgen Inc. will expand its Ohio biomanufacturing facility for $900 million, after a recent move to invest $1 billion to.

Read More
Johnson & Johnson MedTech’s arm, Shockwave Medical Inc. has started human trials to assess the effectiveness of its coronary intravascular catheter for treating blocked arteries, according to a statement.
Health Medical Pharma

J&J starts trial on coronary pressure wave catheter to clear artery blocks

HQ Team April 13, 2025: Johnson & Johnson MedTech’s arm, Shockwave Medical Inc. has started human trials to assess the effectiveness of its.

Read More
Johnson & Johnson plans to acquire Israel’s privately-held V-Wave Ltd., for an upfront payment of $600 million, according to a statement from the US-based company.
Drugs Pharma

Johnson & Johnson ends late-stage trial of depression drug aticaprant

HQ Team March 7, 2025: Johnson & Johnson is discontinuing the Phase 3 VENTURA clinical trial of its experimental depression drug aticaprant after.

Read More
Johnson & Johnson will acquire Intra-Cellular Therapies Inc., a biopharmaceutical company developing drugs for central nervous system disorders, for $14.6 billion, according to a J&J statement.
Drugs Medical Pharma

Johnson & Johnson to acquire Intra-Cellular Therapies Inc., for $14.6 billion

Johnson & Johnson will acquire Intra-Cellular Therapies Inc., a biopharmaceutical company developing drugs for central nervous system disorders, for $14.6 billion, according to.

Read More
ohnson & Johnson paused its rollout of a heart device to treat atrial fibrillation “out of an abundance of caution,” as it probes four cases of neurovascular events related to the device.
Health Medical Pharma

J&J pauses rollout of heart device in US after ischemic, stroke incidents

ohnson & Johnson paused its rollout of a heart device to treat atrial fibrillation “out of an abundance of caution,” as it probes four.

Read More
Johnson & Johnson’s combination therapy for treating a certain form of cancer without chemotherapy, has been shown to extend patients' lives by more than a year, according to a company statement.
Drugs Health Medical Pharma

J&J’s combination extends lives of cancer patients versus rival drug

Johnson & Johnson’s combination therapy for treating a certain form of cancer without chemotherapy, has been shown to extend patients' lives by more.

Read More
Johnson & Johnson has discontinued its mid-stage trial, evaluating an antiviral drug, mosnodenvir, for the prevention of dengue.
Drugs Health Pharma

Johnson & Johnson stops mid-stage trial of drug for dengue prevention

Johnson & Johnson has discontinued its mid-stage trial, evaluating an antiviral drug, mosnodenvir, for the prevention of dengue.

Read More